Jasper Therapeutics(US:JSPR)2026-01-08 14:02Summary of Jasper Therapeutics Chronic Urticaria Data Update Webinar Company Overview - Company: Jasper Therapeutics (NasdaqCM: JSPR) - Focus: Development of briquilimab for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) Key Points and Arguments Industry and Product Development - Briquilimab: An antibody targeting the KIT receptor, showing promise in treating mast cell-driven diseases, including CSU and CIndU [4][5] - Clinical Trials: Updated data from the BEACON study and an open-label extension study were presented, indicating positive outcomes for briquilimab [4][5] Efficacy and Safety Data - BEACON Study Results: - Six out of eight patients receiving briquilimab achieved complete response (CR) by week three, and four out of six by week 12 [6][9] - Mean reduction of UAS7 scores was 31 points at week 12, indicating significant symptom relief [9][12] - Rapid onset of disease control was observed, with most patients showing improvement within two weeks [9][10] - Open-Label Extension Study: - 63 patients treated with briquilimab showed durable clinical responses, with 65% of CIndU patients achieving CR or partial response (PR) at week 16 [9][15] - A favorable chronic safety profile was reported, with low incidence of KIT-related adverse events [7][20] Future Plans - Phase 2b Study: - Expected to commence in the second half of 2026, involving 75 to 100 adult patients with CSU [8][20] - The study will evaluate two effective dose regimens versus placebo [20] - Dose Selection: - Ongoing analysis of current data will inform the final dose selection for the phase 2b study [24][55] - Consideration of weight-adjusted dosing to optimize efficacy [48][55] Competitive Positioning - Differentiated Product Profile: - Briquilimab's unique mechanism of action and favorable safety profile position it competitively against other therapies targeting the KIT receptor [18][19] - The company believes the data supports a compelling product profile for chronic urticarias [20] Financial Considerations - Capital Requirements: - Current capital is sufficient to support operations through mid-2026, but additional funding will be necessary for future studies [28] - Partnership Opportunities: - The company is open to potential partnerships to support broader development across multiple indications [34] Additional Important Information - CEO Transition: The change in leadership was driven by the need for a new direction as the company progresses into pivotal studies [24] - Regulatory Considerations: The company is preparing to engage with regulatory bodies regarding the phase 2b study design and dose selection [25][46] This summary encapsulates the critical insights from the Jasper Therapeutics webinar, highlighting the company's advancements in chronic urticaria treatment and future strategic directions.